Butterfly Network (NYSE:BFLY – Get Free Report) and Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, earnings, valuation, dividends and analyst recommendations.
Valuation and Earnings
This table compares Butterfly Network and Fresenius SE & Co.”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Butterfly Network | $97.61 million | 24.96 | -$77.06 million | ($0.29) | -31.56 |
| Fresenius SE & Co. | $25.87 billion | 1.16 | $1.43 billion | $0.79 | 16.89 |
Profitability
This table compares Butterfly Network and Fresenius SE & Co.’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Butterfly Network | -66.74% | -33.99% | -22.96% |
| Fresenius SE & Co. | 6.67% | 10.25% | 4.87% |
Institutional and Insider Ownership
37.9% of Butterfly Network shares are owned by institutional investors. 22.0% of Butterfly Network shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Volatility and Risk
Butterfly Network has a beta of 2.08, suggesting that its stock price is 108% more volatile than the S&P 500. Comparatively, Fresenius SE & Co. has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and target prices for Butterfly Network and Fresenius SE & Co., as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Butterfly Network | 1 | 1 | 4 | 0 | 2.50 |
| Fresenius SE & Co. | 0 | 0 | 3 | 0 | 3.00 |
Butterfly Network currently has a consensus price target of $7.25, indicating a potential downside of 20.77%. Given Butterfly Network’s higher probable upside, equities research analysts plainly believe Butterfly Network is more favorable than Fresenius SE & Co..
Summary
Fresenius SE & Co. beats Butterfly Network on 8 of the 14 factors compared between the two stocks.
About Butterfly Network
Butterfly Network, Inc. develops, manufactures, and commercializes ultrasound imaging solutions in the United States and internationally. It offers Butterfly iQ, a handheld and single-probe whole body ultrasound system; Butterfly iQ+ and iQ3 ultrasound devices that can perform whole-body imaging in a single handheld probe integrated with the clinical workflow, and accessible on a user's smartphone, tablet, and almost any hospital computer system; and Butterfly iQ+ Vet, a handheld ultrasound system designed for veterinarians. The company also provides Butterfly system, which includes probes, and related accessories and software subscriptions to healthcare systems, physicians, and healthcare providers through a direct sales force, distributors, and eCommerce channel. In addition, it offers cloud-based software solutions to healthcare systems, teleguidance, in-app educational tutorials, and formal education programs through its Butterfly Academy software, as well as professional services for large scale deployments; and ScanLab, an education-only app provides written walkthroughs and reference imagery to guide real-time educational scanning, enhancing the learning process. Butterfly Network, Inc. was founded in 2011 and is headquartered in Burlington, Massachusetts.
About Fresenius SE & Co.
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.
Receive News & Ratings for Butterfly Network Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Butterfly Network and related companies with MarketBeat.com's FREE daily email newsletter.
